-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-91633 in Relapsed Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CC-91633 in Relapsed Acute Myeloid Leukemia Drug Details:CC-91633 (BMS-986397) is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rusfertide Acetate in Hemochromatosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rusfertide Acetate in Hemochromatosis Drug Details: PTG-300 is under development for the treatment of iron...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MP-101 in Amyotrophic Lateral Sclerosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MP-101 in Amyotrophic Lateral Sclerosis Drug Details:MP-101 is under development for the treatment of Huntington’s disease,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aderamastat in Chronic Obstructive Pulmonary Disease (COPD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Aderamastat in Chronic Obstructive Pulmonary Disease (COPD)Drug Details:Aderamastat (FP-025) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aderamastat in Asthma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Aderamastat in AsthmaDrug Details:Aderamastat (FP-025) is under development for the treatment of house dust mite (HDM)-allergic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aderamastat in Chronic Obstructive Pulmonary Disease (COPD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Aderamastat in Chronic Obstructive Pulmonary Disease (COPD) Drug Details: Aderamastat (FP-025) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aderamastat in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Aderamastat in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) Drug Details: Aderamastat (FP-025) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aderamastat in Asthma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Aderamastat in Asthma Drug Details: Aderamastat (FP-025) is under development for the treatment of house...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FP-045 in Pulmonary Arterial Hypertension
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FP-045 in Pulmonary Arterial Hypertension Drug Details: FP-045 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FP-045 in Fanconi Anemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FP-045 in Fanconi Anemia Drug Details: FP-045 is under development for the treatment of radiation-induced...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.